Ann Prejs
Primary Care · Manasquan, NJNPI 1497365480
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,470 of the $2,204 with a category attached, or 66.7%. 28 manufacturers reported payments, led by Cvrx, Inc. at 40.1% of the total. 2025 is the largest year on record at $1,572, 5.6 times the $280 reported in 2021.
Across 58 payments — averaging $38.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$884
- Astellas Pharma US Inc$266
- E.r. Squibb & Sons, L.L.C.$154
- Alnylam Pharmaceuticals Inc.$140
- Boehringer Ingelheim$102
- Actelion Pharmaceuticals US, Inc.$99
- plus $558 from 22 others
What the payments were for
- Travel & lodging$53124%
- Food & beverage$1,47067%
- Education$2049%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 6 | $884 |
| Astellas Pharma US Inc | 8 | $266 |
| E.r. Squibb & Sons, L.L.C. | 3 | $154 |
| Alnylam Pharmaceuticals Inc. | 2 | $140 |
| Boehringer Ingelheim | 6 | $102 |
| Actelion Pharmaceuticals US, Inc. | 6 | $99 |
| Kestra Medical Technology Services, Inc. | 1 | $73 |
| Imperative Care, Inc | 3 | $70 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Bayer | 2 | $29 |
| Medtronic | 1 | $27 |
| Philips North America LLC | 1 | $26 |
| Chiesi USA, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Silk Road Medical, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Amgen | 1 | $16 |
| Agepha Pharma FZ LLC | 1 | $15 |
| Acacia Pharma Inc | 1 | $15 |
| Abiomed | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$687
- AMVUTTRA$125
- CAMZYOS$124
How this compares
$2,204 in reported general payments places this provider in the 80th percentile of 330 primary care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $34,218 |
| XareltoRivaroxaban | 20 | $26,052 |
| EntrestoSacubitril/Valsartan | 12 | $20,855 |
| FarxigaDapagliflozin Propanediol | 14 | $18,567 |
| Rosuvastatin Calcium | 75 | $1,111 |
| Valsartan | 18 | $1,093 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 26 | $940 |
| Ezetimibe | 32 | $787 |
| Flecainide Acetate | 11 | $683 |
| Metoprolol Succinate | 59 | $665 |
| Atorvastatin Calcium | 56 | $575 |
| Hydralazine Hcl | 28 | $391 |
| Carvedilol | 47 | $372 |
| Amlodipine Besylate | 47 | $343 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $34,21838 claims |
| NovartisEntresto | $20 | $20,85512 claims |
| AstraZenecaFarxiga | $16 | $18,56714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 330 primary care providers in New Jersey.
Other primary care in Manasquan
- Michael Zito GovertNeptune$61K
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
- Shazam BacchusNewark$7K
- Anna NievesBasking Ridge$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.